HTGC

Hercules Capital, Inc. (HTGC) - Q1 2019 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2019. Hercules Capital, Inc. is an internally managed, non-diversified closed-end management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The Company focuses on providing senior secured loans to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors.

Key Financial Metrics

Material Changes vs. Prior Period

• Portfolio Growth: Total investment portfolio value increased to $2.08 billion from $1.88 billion, driven by new fundings of $239.7 million and net unrealized appreciation of $28.0 million.
• Debt Financing: The Company issued $250.0 million in 2028 Asset-Backed Notes in January 2019 and fully repaid $83.5 million of 2024 Notes during the quarter. Total borrowings increased significantly compared to the prior year.
• Income Drivers: Interest income rose to $55.5 million (from $43.0 million) due to a larger loan portfolio and higher core yields. Fee income decreased to $3.3 million (from $5.7 million) due to lower acceleration of fees from early repayments.
• Realized Gains: The Company recorded net realized gains of $4.6 million, a reversal from the $4.9 million loss in Q1 2018, primarily due to M&A transactions and sales of portfolio holdings.
• Unrealized Appreciation: Significant unrealized appreciation of $28.0 million was recorded, largely driven by equity and warrant valuations, contrasting with the $15.2 million depreciation in the prior year.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue generating current income from debt investments and capital appreciation from equity/warrants. The Company maintains a variable distribution policy targeting 90-100% of taxable income.
• Distributions: A quarterly distribution of $0.31 per share was declared for Q1 2019. Subsequent to the period end, a Q2 distribution of $0.32 per share plus a $0.01 supplemental distribution was declared.
• Liquidity: As of March 31, 2019, the Company had approximately $247.2 million in available liquidity, including cash and undrawn credit facilities (Wells and Union Bank).
• Risks:
  • Concentration Risk: The top 10 portfolio companies represented 26.2% of the total portfolio fair value. Eight investments represented 5% or more of net assets.
  • Valuation Risk: Approximately 97.3% of assets are Level 3 investments valued in good faith by the Board, which may differ from market values if a liquid market existed.
  • Interest Rate Risk: While 97.5% of the debt portfolio has floating rates, rising rates increase borrowing costs on fixed-rate debt (e.g., Notes and SBA debentures).
  • Portfolio Performance: Two debt investments were on non-accrual status with a fair value of $0.5 million.

Key Facts for Investor Verification

• NAV vs. Market Price: Verify the trading price of HTGC common stock relative to the reported NAV of $10.26 per share.
• Debt Maturity Profile: Review the maturity schedule of the $1.14 billion in outstanding borrowings, noting the significant issuance of 2028 Asset-Backed Notes.
• Unfunded Commitments: Confirm the $154.2 million in unfunded contractual commitments available at the request of portfolio companies.
• Portfolio Concentration: Monitor the performance of the top 8 holdings (e.g., Paratek Pharmaceuticals, EverFi, BridgeBio Pharma) which collectively represent over 40% of net assets.
• Asset Coverage Ratio: Verify the BDC asset coverage ratio (199.4% excluding SBA debentures) to ensure compliance with the 150% minimum requirement.